ReShape Lifesciences

ReShape Lifesciences

Developer of minimally invasive medical devices to treat obesity and metabolic diseases.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

€0.0

round
investor investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor investor

€0.0

round
investor investor

€0.0

round
investor investor

€0.0

round
N/A

€0.0

round
investor

€0.0

Valuation: €0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
*
N/A

$2.6m

Post IPO Equity
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2018201920202021202220232024
Revenues0000000000000000000000000000
% growth7 %2386 %(25 %)20 %(17 %)(23 %)(8 %)
EBITDA0000000000000000000000000000
% EBITDA margin(6303 %)(114 %)(110 %)(204 %)(222 %)(203 %)(83 %)
Profit0000000000000000000000000000
% profit margin(13369 %)(492 %)(191 %)(455 %)(411 %)(131 %)(89 %)
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue943 %21 %31 %19 %23 %27 %23 %

Source: Company filings or news article

More about ReShape Lifesciences
Made with AI
Edit

ReShape Lifesciences, Inc. specializes in developing minimally invasive medical devices aimed at treating obesity and metabolic diseases. The company's product portfolio includes the Adjustable Gastric Banding System and the investigational ReShape Vest, which is designed to assist more patients in managing obesity. ReShape Lifesciences operates primarily in the healthcare sector, targeting bariatric surgeons and medical professionals who treat obesity. The company generates revenue through the sale of its medical devices and related services. ReShape Lifesciences is also actively involved in clinical trials, such as the ENDURE II trial in the European Union, to support regulatory approvals and expand its market reach. The business model focuses on innovation in medical technology to provide effective, less invasive treatment options for obesity, thereby improving patient outcomes and expanding its market presence.

Keywords: obesity treatment, metabolic diseases, medical devices, Adjustable Gastric Banding, ReShape Vest, bariatric surgery, healthcare innovation, clinical trials, regulatory approval, patient outcomes.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by ReShape Lifesciences

Edit
Obalon Therapeutics
ACQUISITION by ReShape Lifesciences Jun 2021